AstraZeneca's Covid "vaccine" Vaxzevria is no longer approved in the EU!

AstraZeneca's so-called Covid-19 vaccine, which politicians and the establishment media claimed was "safe", "tested", "effective" and "free of side effects", will no longer be approved in the European Union as of 7 May 2024. AstraZeneca itself submitted an application for withdrawal of the marketing authorisation, which was confirmed by the EU. You can find the original document in this article.

On 27 March 2024, the EU Commission announced the withdrawal of the marketing authorisation for the Covid-19 vaccine ChAdOx1-S [recombinant], also known as Vaxzevria Covid-19 vaccine, at the request of the patent holder.

The relevant document can also be found here From the European Commission website . What the withdrawal of a marketing authorisation means in practice, you can find here .

Below you can see the EU document on the withdrawal of marketing authorisations.

Machine-assisted translation

COMMISSION IMPLEMENTATION DECISION adopted
27.3.2024
Withdrawal of marketing authorisation for the medicinal product "Vaxzevria - COVID-19 Vaccine (ChAdOx1-S [recombinant])" for human use granted by Decision C(2021) 698(final) at the request of the holder

EUROPEAN COMMISSION,
Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1), Having regard to the application submitted by AstraZeneca AB on 5 March 2024 for the withdrawal of the marketing authorisation for the medicinal product 'Vaxzevria - COVID-19 vaccine (ChAdOx1-S (recombinant)',

and consider the following:

(1) The placing on the market of the medicinal product 'Vaxzevria - COVID-19 vaccine (ChAdOx1-S (recombinant))', registered in the Union Register of Medicinal Products under No EU/1/21/. 1529, was authorised by Commission Decision C(2021) 698 final of 29 January 2021.

(2) This authorisation should be withdrawn at the request of the holder, HAS ADOPTED THIS DECISION:

Article 1
At the request of the holder, the marketing authorisation for the medicinal product "Vaxzevria - COVID-19 vaccine (ChAdOx1-S [recombinant])", granted by Decision C(2021) 698(final) of 29 January 2021, is withdrawn.

2 §
The repeal referred to in paragraph 1 shall enter into force on 7 May 2024.

Article 3
This Decision is addressed to AstraZeneca AB, 151 85 Södertälje, Sweden.
Done at Brussels, 27 March 2024.